Search Results
Nov 12, 2025, 08:00 ET Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
advanced colorectal cancer (CRC) at the European Society for Medical Oncology (ESMO) Congress. In addition, we will be engaging with regulatory authorities to seek a registrational pathway for sirexatamab and optimizing the DKK1 biomarker assay that could be used to identify CRC patients at risk of poor
More news about: Cypherpunk Technologies Inc.
Nov 10, 2025, 07:00 ET Freenome Appoints Industry Veteran Rob Guigley as Chief Commercial Officer to Drive Commercial Strategy, As Agreement with Exact Sciences Clears Antitrust Review
version of the test, known as SimpleScreen™ CRC in the FDA filing, with approval expected in the second half of 2026. "As we transition to this new phase, we are focused on strengthening our commercial leadership to maximize the reach of our CRC test while aggressively advancing our
More news about: Freenome Holdings, Inc.
Nov 07, 2025, 09:00 ET Marengo Late-Breaking Oral Presentation Highlights Single-Agent, Pan Tumor Activity of Invikafusp Alfa Across PD-1-Resistant Cancers in Phase 2 Clinical Trial at SITC 2025
GEJ, head and neck, and bladder cancersResponses by indication include gastrointestinal (GI) tumors (28% ORR, 78% DCR), colorectal cancer (CRC) (33% ORR, 67% DCR), and non-small cell lung cancer (NSCLC) (20% ORR, 80% DCR)Target tumor shrinkage, with 59% of patients experiencing target-lesion
More news about: Marengo Therapeutics
Nov 06, 2025, 07:30 ET Continuum Recovery Center of Colorado Selects the Janus Contingency Management Platform to Strengthen Addiction Treatment Services
of Q2i. "We're proud to partner with CRC to make this proven treatment more accessible and to support their commitment to whole-person, compassionate care." With a team of licensed therapists, medical providers, and counselors, CRC takes a 365-degree approach to treating
More news about: Q2I
Nov 04, 2025, 12:00 ET Chainlink Runtime Environment Goes Live, Unlocking Institutional Tokenization at Scale
are implementing CRE in Project Acacia, a new joint initiative between the Reserve Bank of Australia and Digital Finance CRC (DFCRC), to orchestrate DvP settlement of tokenized assets. The Bermuda Monetary Authority and Apex completed
More news about: Chainlink
Nov 03, 2025, 09:05 ET Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition
met inclusion criteria for the study. The overall response rate (ORR) was 50% (7/14) and the composite complete remission (CRc) rate was 36% (5/14). Among patients who achieved any response, 86% (6/7) received venetoclax immediately prior to olutasidenib.
More news about: Rigel Pharmaceuticals, Inc.
Nov 02, 2025, 23:12 ET Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer
first-line triple-negative breast cancer. Additionally, Phase III studies are underway for first-line MSS/pMMR colorectal cancer (which accounts for 95% of CRC cases) and first-line pancreatic cancer. Further Phase III studies are also being prepared. With nearly 20 Phase II studies across
More news about: Akeso, Inc.
Oct 29, 2025, 08:30 ET Caris Data Validates TET2 Clonal Hematopoiesis as a Biomarker for Enhanced Immunotherapy Response
clinico-genomic database, analyzing outcomes in a real-world cohort of nearly 36,000 patients with non-small cell lung cancer (NSCLC) and over 25,000 colorectal (CRC) cancer patients. This dual approach provided insight and large-scale evidence supporting TET2-CH as a potential biomarker for enhanced ICI response.
More news about: Caris Life Sciences
Oct 28, 2025, 11:00 ET Legal 1031 Exchange Services Hires Tarra Chen as Exchange Director for the Mid-Atlantic Region
developers, operators, opportunity funds, commercial lenders, family offices, realtors and regional and national residential lenders. The company is part of CRC Group, one of North America's largest independent wholesale specialty insurance distributors, delivering the broadest range of insurance solutions available
More news about: Kensington Vanguard National Land Services
Oct 28, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
(Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC)." The press release disclosed that while the drug achieved one of its dual primary endpoints, showing a modest Overall Survival gain, the second endpoint
More news about: Pomerantz LLP
Oct 28, 2025, 04:23 ET One Lantern, Three Destinations! 3.2 Million Fans Follow IN XI'AN to Discover a City Where Ancient Meets Modern
Xi'an. According to the China City Overseas Social Media Communication Impact Index (August 2025), jointly released by Reference Think Tank and CRC Index, Xi'an ranked third in overall communication influence that month. The consistent presence of IN XI'AN has added a compelling case study to the
More news about: In Xi'an
Oct 24, 2025, 02:32 ET Mastering Management Education in Real-Time: The ICFAI Business School (IBS) Approach to Case-Based Learning
School (IBS) Hyderabad, emphasizes a practical, case-based learning approach. This method is highlighted by the institution's Case Research Center (CRC), which was ranked second globally by the Case Centre's Impact Index 2024, placing it just behind Harvard.
More news about: ICFAI Business School (IBS)
Oct 23, 2025, 17:31 ET Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight
depending on cohort and geography; some studies report up to 26% in some settings, but typically 13–15% is most consistent for unselected CRC. Leading mismatch repair deficiency companies developing emerging therapies, such as Arcus Biosciences, Gilead Sciences,
More news about: DelveInsight Business Research, LLP
Oct 23, 2025, 16:05 ET Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
results from the Phase 1 trial of ozekibart in combination with FOLFIRI for the treatment of advanced or metastatic, unresectable colorectal cancer (CRC), Inhibrx initiated an expansion cohort enrolling 44 patients, as a fourth line of therapy for approximately 70% of patients and as a third line of therapy
More news about: Inhibrx Biosciences, Inc.
Oct 23, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
(Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC)." The press release disclosed that while the drug achieved one of its dual primary endpoints, showing a modest Overall Survival gain, the second endpoint
More news about: Pomerantz LLP
Oct 22, 2025, 20:00 ET Harbour BioMed Announces Positive Phase II Results for HBM4003 and Tislelizumab Combination in MSS mCRC
data have been observed in the monotherapy trial targeting advanced solid tumors, as well as in combination trials with PD-1 inhibitors for melanoma, CRC, NEN and HCC. Final data from the study of HBM4003 in combination with toripalimab for advanced HCC were published in Clinical Cancer Research
More news about: Harbour BioMed
Oct 22, 2025, 09:53 ET U.S. oil and gas M&A slumps as low crude prices keep buyers in the dugout
Energy (VTLE) for more than $3 billion in stock and assumed debt and Berry Petroleum's (BRY) $717 million sale to California Resources Corporation (CRC). "Consolidation among SMID-cap companies is becoming the obvious strategic path forward in U.S. oil and gas M&A as high-quality
More news about: Enverus
Oct 21, 2025, 20:25 ET Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
clinical data of over 1,200 treated patients, IBI363 will be initially developed globally in non-small cell lung cancer ("NSCLC") and colorectal cancer ("CRC"), including in the first-line settings. Additionally, Takeda and Innovent plan to expand IBI363's clinical development to additional indications.
More news about: Innovent Biologics
Oct 20, 2025, 07:00 ET Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
prognostic factor and elevated in patients with advanced, metastatic CRC. The data presented at ESMO demonstrate that sirexatamab, which binds to and removes free DKK1, has significant potential to provide a survival benefit for CRC patients who have high DKK1 levels and who are likely to have poor outcomes
More news about: Leap Therapeutics, Inc.
Oct 17, 2025, 14:30 ET Orthodox Jews to Rally Outside Israeli Consulate Against the Forced Conscription of Religious Jews
CENTRAL RABINICAL CONGRESS The Central Rabbinical Congress of the U.S.A. and Canada, commonly referred to as the CRC; or Hisachdus HaRabbonim D'Artzos HaBris V'Canada (התאחדות הרבנים, its Hebrew name), is a rabbinical organization that is a consortium of many Orthodox
More news about: The Central Rabbinical Congress of the U.S.A. and Canada
Oct 14, 2025, 02:19 ET Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-TKI, a Novel Multi-tyrosine Kinase Inhibitor with Potent Immune Activation, at the 2025 ESMO Annual Meeting
(TKs), including TAM (TYRO3, AXL, and c-MER), are critical in creating environment conducive to tumor development in several cancers such as HNSCC, CRC, HCC, and RCC. GNTbm-TKI is a novel multi-targeted TKI, showing induction of immune activation in the tumor microenvironment (TME), that indicates the
More news about: Great Novel Therapeutics Biotech & Medicals Corporation
Oct 13, 2025, 14:45 ET Family Research Council Releases New Study Showing Shifting Views of U.S. Churchgoers
Cultural Research Center at Arizona Christian University (CRC) today released a new national survey of 1,003 regular churchgoing adults (July 2025), updating a comparable
More news about: Family Research Council
Oct 13, 2025, 08:43 ET AccuGenomics and 1Cell.Ai Partner to Bring Ultra-Sensitive Liquid Biopsy Testing Across Asia, with Plans for U.S. Expansion
States market soon. The Accukit™ CRC/NSCLC Internal Standards are synthetic, gene-specific quality controls that validate assay performance and ensure sensitivity for detecting clinically relevant mutations in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). By embedding
More news about: AccuGenomics
Oct 13, 2025, 07:15 ET AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
Combination with bevacizumab (Bev) in Colorectal Cancer (CRC): In biomarker unselected patients with advanced CRC who have received three or more prior lines of therapy (
More news about: AbbVie
Oct 09, 2025, 08:22 ET Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission
actively advancing an international multi-centre phase 3 clinical study evaluating HANSIZHUANG-based combinations in the first-line treatment of metastatic CRC (mCRC). Concurrently, the company continues to push the boundaries of GI cancer treatment by developing next-generation therapies, such as the PD-L1-targeting
More news about: Henlius